Updated from 7:19 a.m. EDTEli Lilly ( LLY) swung to a second-quarter profit Friday as sales rose 5% from a year ago, but the company trimmed its full-year revenue guidance. For the three months ended June 30, Lilly earned 76 cents a share, excluding special items, or a penny better than the Thomson First Call consensus. Revenue of $3.87 billion matched the average analyst estimate. For the full year, Lilly said EPS would be in the range of $3.10 to $3.20 compared with the average analyst target of $3.13. Both predictions exclude one-time items. Lilly said full-year sales growth would be at the low end of its previously forecast 7% to 9% increase. On a reported basis, Lilly earned $822 million, or 76 cents a share, on revenue of $3.87 billion for the second quarter. For the same period last year, Lilly lost $252 million, or 23 cents a share, on revenue of $3.67 billion. Last year's quarter was affected by a pretax charge of $1.07 billion, or 90 cents a share after tax. The charge was for settling lawsuits that claimed Lilly didn't adequately inform doctors and patients about the side effects of the schizophrenia drug Zyprexa. Lilly's stock recently fell $1.34, or 2.4%, to $54.92. As Lilly's biggest product, Zyprexa continues to command attention from analysts. For the second quarter, worldwide sales rose 2% from the year-ago quarter to $1.12 billion. U.S. sales slipped 1% to $542.9 million. U.S. sales were affected by lower demand, which was partly offset by higher prices, Lilly said. The company sees "improving prescription trends" because U.S. prescriptions "have held steady" during the first half of the year. However, at the beginning of the year, Lilly was counting on a better performance by Zyprexa, especially in the U.S., said John Lechleiter, president and chief operating officer, in a conference call with analysts. Slower-than-expected growth for Zyprexa and for insulin products are the main reasons why the full-year sales-growth forecast will be at the lower end of Lilly's predicted range.